Meeting
2023 ASCO Annual Meeting
Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma.
Authors
Yang Liu
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
Yang Liu , Wensu Wei , Zhiling Zhang , Ruiqi Liu , Jianming Gao , Shengjie Guo , Hui Han , Pei Dong , Liru He , Fangjian Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
ChiCTR1800017136
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4533)
DOI
10.1200/JCO.2023.41.16_suppl.4533
Abstract #
4533
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2021 Genitourinary Cancers Symposium
Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.
First Author: İzzet Dogan
Poster
2017 ASCO Annual Meeting
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.
First Author: Georg A. Bjarnason
Poster
2012 ASCO Annual Meeting
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
First Author: Ian D. Davis